Abstract
Background: Skin autofluorescence (SAF), as a proxy of AGE accumulation, is predictive of cardiovascular (CVD) complications in i.a. type 2 diabetes mellitus and renal failure, independently of most conventional CVD risk factors. The present exploratory substudy of the Groningen Overweight and Lifestyle (GOAL)-project addresses whether SAF is related to Systematic COronary Risk Evaluation (SCORE) risk estimation (% 10-year CVD-mortality risk) in overweight/obese persons in primary care, without diabetes/renal disease, and if after 3-year treatment of risk factors (change in, Delta) SAF is related to Delta SCORE.
Methods: In a sample of 65 participants from the GOAL study, with a body mass index (BMI) >25-40 kg/m(2), hypertension and/or dyslipidemia, but without diabetes/renal disease, SAF and CVD risk factors were measured at baseline, and after 3 years of lifestyle and pharmaceutical treatment.
Results: At baseline, the mean SCORE risk estimation was 3.1 +/- 2.6%, mean SAF 2.04 +/- 0.5AU. In multivariate analysis SAF was strongly related to age, but not to other risk factors/SCORE. After 3 years Delta SAF was 0.34 +/- 0.45 AU (p
Conclusions: Baseline and 3-year-Delta SAF are not related to (Delta) SCORE, or its components, except age, in the studied population. Delta SAF was negatively related to Delta weight. As 3-year SAF was higher in persons with CVD, these results support a larger study on SAF to assess its contribution to conventional risk factors/SCORE in predicting CVD in overweight persons with low-intermediate cardiovascular risk.
Original language | English |
---|---|
Pages (from-to) | 121-127 |
Number of pages | 7 |
Journal | Clinical chemistry and laboratory medicine |
Volume | 52 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan-2014 |
Keywords
- cardiovascular
- SCORE risk estimation
- skin autofluorescence
- ADVANCED GLYCATION ENDPRODUCTS
- SYSTEMIC-LUPUS-ERYTHEMATOSUS
- TYPE-2 DIABETES-MELLITUS
- LIFE-STYLE INTERVENTION
- PREVENTING WEIGHT-GAIN
- CHRONIC KIDNEY-DISEASE
- END-PRODUCTS
- COMPLICATIONS
- MARKER